PURPOSE: Delivery of therapeutic proteins across the blood-brain barrier (BBB) is severely limited by their size and biochemical properties. Here we showed that a 39-amino acid peptide derived from the rabies virus glycoprotein (RDP) was exploited as an efficient protein carrier for brain-targeting delivery. METHODS: Three proteins with different molecular weight and pI, β-galactosidase (β-Gal), luciferase (Luc) and brain-derived neurotrophic factor (BDNF), were fused to RDP and intravenously injected into the mice respectively. The slices of different tissues with X-Gal staining were used to examine whether RDP could deliver β-Gal targeted into the CNS. The time-course relationship of RDP-Luc was studied to confirm the transport efficiency of RDP. The neuroprotective function of RDP-BDNF was examined in mouse experimental stroke to explore the pharmacological effect of RDP fusion protein. RESULTS: The results showed that the fusion proteins rapidly and specific entered the nerve cells in 15 min, and the t(1/2) was about 1 hr. Furthermore, RDP-BDNF fusion protein showed the neuroprotective properties in mouse experimental stroke including reduction of stroke volume and neural deficit. CONCLUSIONS: RDP provides an effective approach for the targeted delivery of biological active proteins into the central nervous system.
PURPOSE: Delivery of therapeutic proteins across the blood-brain barrier (BBB) is severely limited by their size and biochemical properties. Here we showed that a 39-amino acid peptide derived from the rabies virus glycoprotein (RDP) was exploited as an efficient protein carrier for brain-targeting delivery. METHODS: Three proteins with different molecular weight and pI, β-galactosidase (β-Gal), luciferase (Luc) and brain-derived neurotrophic factor (BDNF), were fused to RDP and intravenously injected into the mice respectively. The slices of different tissues with X-Gal staining were used to examine whether RDP could deliver β-Gal targeted into the CNS. The time-course relationship of RDP-Luc was studied to confirm the transport efficiency of RDP. The neuroprotective function of RDP-BDNF was examined in mouse experimental stroke to explore the pharmacological effect of RDP fusion protein. RESULTS: The results showed that the fusion proteins rapidly and specific entered the nerve cells in 15 min, and the t(1/2) was about 1 hr. Furthermore, RDP-BDNF fusion protein showed the neuroprotective properties in mouse experimental stroke including reduction of stroke volume and neural deficit. CONCLUSIONS: RDP provides an effective approach for the targeted delivery of biological active proteins into the central nervous system.
Authors: Shi-Rong Cai; Guang Xu; Michelle Becker-Hapak; Margaret Ma; Steven F Dowdy; Howard L McLeod Journal: Eur J Pharm Sci Date: 2006-01-11 Impact factor: 4.384
Authors: N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous Journal: Hum Mol Genet Date: 2001-09-15 Impact factor: 6.150
Authors: Rebecca L Cook; Kyle T Householder; Eugene P Chung; Alesia V Prakapenka; Danielle M DiPerna; Rachael W Sirianni Journal: J Control Release Date: 2015-10-22 Impact factor: 9.776
Authors: Paul A Gramlich; Wendy Westbroek; Ricardo A Feldman; Ola Awad; Nicholas Mello; Mary P Remington; Ying Sun; Wujuan Zhang; Ellen Sidransky; Michael J Betenbaugh; Paul S Fishman Journal: J Biotechnol Date: 2016-01-18 Impact factor: 3.307